Navigation Links
Jennerex Completes $8.3 Million Series B Financing and Appoints Dr. Cal Stiller as Director
Date:9/9/2008

Clinical Trial Programs Funded Through 2009

SAN FRANCISCO, Sept. 9 /PRNewswire/ -- Jennerex, Inc. (San Francisco, CA and Ottawa, Ontario), a clinical stage biopharmaceutical company developing a proprietary breakthrough class of targeted oncolytic virus therapeutics, today announced the closing of a financing transaction with gross proceeds of $8.3 million USD, exceeding the target of $8 million USD. The offering was completed without the services of an agent.

The net proceeds of the private placement will be used to advance the Company's clinical development programs, including lead product JX-594, which is currently being evaluated in a randomized Phase II clinical trial for liver cancer. This is one of three clinical trials currently under way, which also include a Phase II trial for colon cancer and a Phase I trial targeting lung cancer and other solid tumors. Proceeds from the financing will also be used for research and development, general corporate purposes and to augment working capital.

"We are extremely pleased by the enthusiastic support of existing shareholders, and we welcome several new shareholders to the Company," said David H. Kirn, M.D., President and CEO of Jennerex. "This funding is expected to cover operations for the next 18 months, through the end of 2009, and specifically to fund the company through significant value inflection points, including completion of the above-mentioned clinical trials," said Dr. Kirn.

Jennerex also announces the appointment of Calvin Stiller, CM, O. ONT, MD, F.R.C.P. (C) to the Company's Board of Directors. Dr. Stiller is Chairman of the board and Chief Executive Officer of Stilco Corporation and BioQuest Innovations Inc. Dr. Stiller has also served as a director of NPS Pharmaceuticals Inc. since December 1999; and had served on the board of Allelix since April 1999 until its acquisition by NPS. From 1996 to 2005, Dr. Stiller served as Chairman and Chief Executive Offi
'/>"/>

SOURCE Jennerex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Jennerex Appoints Bob Ingram Special Advisor and Hires Marty Glick as EVP, Corporate Strategy
2. Neptune Technologies successfully completes up to $8.5 million debt financing with Desjardins Group
3. Genesis Pharmaceuticals Completes Reverse Stock Split and Will Trade Under a New Symbol
4. Osprey Pharmaceuticals U.S.A., Inc. Completes $11 Million Initial Private Financing
5. Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman
6. Oncolytics Biotech Inc. Completes Dose Escalation in Combination REOLYSIN(R)/Docetaxel Trial
7. Renowned NJ-Based Video Assisted Thoracic Surgery (VATS) Team Completes 5,000th Successful Procedure
8. BioMS Medical completes patient recruitment in phase III U.S. multiple sclerosis trial
9. Sierra Neuropharmaceuticals Completes $21.5-Million Series A Funding Round
10. NuVasive Completes Acquisition of Osteocel Biologics Business
11. Hologic Completes Cash Tender Offer for Third Wave Technologies, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/27/2014)... October 27, 2014 The report ... Intelligent Traffic Management, Communication, Monitoring), and by Display ... to 2019” segments the global market into various ... It also identifies the drivers and restraints for ... challenges. , Browse 75 market tables and 37 ...
(Date:10/27/2014)... Pa. , Oct. 27, 2014 ... Foundation of America (CCFA) announced today the launch ... , an educational campaign designed to ... diseases (IBD) on the paired role of nutrition ... To view the multimedia assets associated with this ...
(Date:10/26/2014)... (PRWEB) October 26, 2014 The ... Routers, ADC, Network Security Equipment, WAN Optimization Appliances]: ... and segments the data center networking market into ... of revenues. The report also identifies the factors ... opportunities impacting it along with the future roadmaps. ...
(Date:10/25/2014)... 25, 2014 The report “Adipic ... by Geography - Global Trends & Forecast to ... respect to market drivers, opportunities, and trends in ... and 27 figures spread through 217 slides and ... Trends & Forecast to 2019”., http://www.marketsandmarkets.com/Market-Reports/adipic-acid-269.html , ...
Breaking Biology Technology:Smart Highway Market by Technology, and Display Expected to Reach $27.992.0 Million by 2019- New Report by MarketsandMarkets 2Smart Highway Market by Technology, and Display Expected to Reach $27.992.0 Million by 2019- New Report by MarketsandMarkets 3Smart Highway Market by Technology, and Display Expected to Reach $27.992.0 Million by 2019- New Report by MarketsandMarkets 4Celebrity Cook Sunny Anderson Teams Up With Janssen And Crohn's & Colitis Foundation Of America To Launch Educational Campaign 2Celebrity Cook Sunny Anderson Teams Up With Janssen And Crohn's & Colitis Foundation Of America To Launch Educational Campaign 3Celebrity Cook Sunny Anderson Teams Up With Janssen And Crohn's & Colitis Foundation Of America To Launch Educational Campaign 4Data Center Networking Market by Ethernet Switches, SAN & Routers Worth $21.85 Billion by 2018 - New Report by MarketsandMarkets 2Data Center Networking Market by Ethernet Switches, SAN & Routers Worth $21.85 Billion by 2018 - New Report by MarketsandMarkets 3Data Center Networking Market by Ethernet Switches, SAN & Routers Worth $21.85 Billion by 2018 - New Report by MarketsandMarkets 4Adipic Acid Market Estimated to Grow $7,539.2 Million by 2019 - Report by MarketsandMarkets 2Adipic Acid Market Estimated to Grow $7,539.2 Million by 2019 - Report by MarketsandMarkets 3Adipic Acid Market Estimated to Grow $7,539.2 Million by 2019 - Report by MarketsandMarkets 4
... Quarter 2009 Financial ResultsVANCOUVER, April 16 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, ... a conference call discussing its financial results for the first ... at 11:00 AM ET (8:00 AM Pacific)., ... is as, follows:, North ...
... Aspheric NTIOL Implanted through the Smallest Micro-Incision using ... Assist Ophthalmic PracticesMONROVIA, Calif., April 16 STAAR ... leading developer, manufacturer and marketer of minimally invasive ... Afinity Collamer Aspheric Single Piece New Technology Intraocular ...
... April 15 Cytopia Limited (ASX: CYT) announced that ... agent (VDA) CYT997 at the forthcoming 100th Annual Meeting ... Colorado, USA. Dr David Segal, Principal Scientist at Cytopia, ... Research: Experimental and Molecular Therapeutics 2 poster session ...
Cached Biology Technology:STAAR Surgical Releases Afinity(TM) Collamer(R) Aspheric Single Piece NTIOL 2STAAR Surgical Releases Afinity(TM) Collamer(R) Aspheric Single Piece NTIOL 3STAAR Surgical Releases Afinity(TM) Collamer(R) Aspheric Single Piece NTIOL 4STAAR Surgical Releases Afinity(TM) Collamer(R) Aspheric Single Piece NTIOL 5Cytopia Presentation on VDA CYT997 at AACR Conference 2
(Date:10/29/2014)... ceremony held in New York City on September 19, ... American Cancer Society Professor of Genome Sciences and Medicine ... Honorary Doctor of Philosophy of Tel Aviv University, was ... Science. , In addition to her honorary degree from ... the TAU School of Medicine, and for the past ...
(Date:10/29/2014)... One kind of stem cell, those referred to as ... There is apparently nothing that differentiates these cells from ... namely they retain the capacity to become stem cells ... liver, an organ that hosts cells that stimulate tissue ... the case of a transplant. Knowledge of the ...
(Date:10/29/2014)... living world compete with members of their own ... they invest into their competitive ability. Some individuals ... to high-quality resources, while others seem to avoid ... resources that are left over for them. Moreover, ... societies seems to fluctuate considerably over time. A ...
Breaking Biology News(10 mins):Geneticist and humanitarian: Prof. Mary-Claire King receives Lasker Award 2A mechanism that allows a differentiated cell to reactivate as a stem cell revealed 2Evolution of competitiveness 2Evolution of competitiveness 3
... international collaborators have discovered the key to overcoming three ... growers worldwide in excess of AUS$7.8 billion. In ... Science , scientists from CSIRO Plant Industry, the University ... Center have identified a wheat gene sequence which provides ...
... Cardiovascular Research Institute, Colchester, Vermont have found that ... inhibitor type-1 (PAI-1) is profibrotic. The results, ... Experimental Biology and Medicine , implicate PAI-1 ... 2 diabetes, as a factor contributing to the ...
... Princeton, NJ February 23, 2009 - A new ... the Intergovernmental Panel on Climate Change (IPCC) 2001 Third ... increase in average global temperatures due to greenhouse gas ... of global concern. The study, published in the ...
Cached Biology News:Saving wheat crops worldwide 2Plasminogen activator inhibitor type-1 -- a potential link between heart failure and diabetes 2Lower increases in global temps could lead to greater impacts than previously thought, study finds 2Lower increases in global temps could lead to greater impacts than previously thought, study finds 3
...
Jak3 Antibody Ship: Hot Store: -20 C...
WASF2 Immunogen: WASF2 (NP_008921, 73 a.a. ~ 173 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Applications: Western blotting Stability: Room temperature, indefinitely ...
Biology Products: